Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed

Journal of Structural Biology

Volumn 192, Issue 3, 2015, Pages 539-544

  Yosaatmadja, Yuliana ^a   Silva, Shevan ^b   Dickson, James M ^a   Patterson, Adam V ^b,c   Smaill, Jeff B ^b,c   Flanagan, Jack U ^b,c   McKeage, Mark J ^b,c   Squire, Christopher J ^a,c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Cancer; Drug design; Epidermal growth factor receptor kinase; Mutation; Protein structure

Indexed keywords

ALANINE; DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCINE; LEUCINE; N [3 [[5 CHLORO 2 [[2 METHOXY 4 (4 METHYL 1 PIPERAZINYL)PHENYL]AMINO] 4 PYRIMIDINYL]OXY]PHENYL]ACRYLAMIDE; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL]ACRYLAMIDE; OSIMERTINIB; PHENYLALANINE; SERINE; VALINE; ACRYLAMIDE DERIVATIVE; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; ERLOTINIB; GEFITINIB; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ALKYLATION; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; HYDROGEN BOND; MOLECULAR DOCKING; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN MODIFICATION; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; GENETICS; HUMAN; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; PHYSIOLOGY; ULTRASTRUCTURE; X RAY CRYSTALLOGRAPHY;

ACRYLAMIDES; ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, NEOPLASM; ERLOTINIB HYDROCHLORIDE; HUMANS; LUNG NEOPLASMS; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84946867131     PISSN: 10478477     EISSN: 10958657     Source Type: Journal    
DOI: 10.1016/j.jsb.2015.10.018     Document Type: Article

References (50)

1. Allen L.F., Eiseman I.A., Fry D.W., Lenehan P.F. CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer. Semin. Oncol. 2003, 30(Suppl. 16):65-78.
2. Brewer R., Yun C.H., Lai D., Lemmon M.A., Eck M.J., Pao W. Mechanism for activation of mutated epidermal growth factor receptors in lung cancer. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:E3595-E3604.
3. Brzezniak C., Carter C.A., Giaccone G. Dacomitinib, a new therapy for the treatment of non-small cell lung cancer. Expert Opin. Pharmacother. 2013, 14:247-253.
4. Calvo E., Tolcher A.W., Hammond L.A., Patnaik A., de Bono J.S., Eiseman I.A., Olson S.C., Lenehan P.F., McCreery H., LoRusso P., Rowinsky E.K. Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study. Clin. Cancer Res. 2004, 10:7112-7120.
5. Cancer Genome Atlas Research Network Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014, 511:543-550.
6. Carey K.D., Garton A.J., Romero M.S., Kahler J., Thomson S., Ross S., et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res. 2006, 66:8163-8171.
7. Chen V.B., Arendall W.B., Headd J.J., Keedy D.A., Immormino R.M., Kapral G.J., Murray L.W., Richardson J.S., Richardson D.C. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. 2010, D66:12-21.
8. Cross D.A., Ashton S.E., Ghiorghiu S., Eberlein C., Nebhan C.A., Spitzler P.J., et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discovery 2014, 4:1046-1061.
9. Dar A.C., Lopez M.S., Shokat K.M. Small molecule recognition of c-Src via the Imatinib-binding conformation. Chem. Biol. 2008, 15:1015-1022.
10. Deininger M., Buchdunger E., Druker B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005, 105:2640-2653.
11. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
12. Emsley P., Lohkamp B., Scott W.G., Cowtan K. Features and development of coot. Acta Crystallogr. 2010, D66:486-501.
13. Engelman J.A., Zejnullahu K., Gale C.-M., Lifshits E., Gonzales A.J., Shimamura T., Zhao F., Vincent P.W., Naumov G.N., Bradner J.E., Althaus I.W., Gandhi L., Shapiro G.I., Nelson J.M., Heymach J.V., Meyerson M., Wong K.-K., Jänne P.A. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 2007, 67:11924-11932.
14. Evans P.R., Murshudov G.N. How good are my data and what is the resolution?. Acta Crystallogr. Sect. D. 2013, D69:1204-1214.
15. Finlay M.R., Anderton M., Ashton S., Ballard P., Bethel P.A., Box M.R., et al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J. Med. Chem. 2014, 57:8249-8267.
16. Gajiwala K.S., Feng J., Ferre R., Ryan K., Brodsky O., Weinrich S., et al. Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition. Structure 2013, 21:209-219.
17. Gonzales A.J., Hook K.E., Althaus I.W., Ellis P.A., Trachet E., Delaney A.M., Harvey P.J., Ellis T.A., Amato D.M., Nelson J.M., Fry D.W., Zhu T., Loi C.-M., Fakhoury S.A., Schlosser K.M., Sexton K.E., Winters R.T., Reed J.E., Bridges A.J., Lettiere D.J., Baker D.A., Yang J., Lee H.T., Tecle H., Vincent P.W. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol. Cancer Ther. 2008, 7:1880-1889.
18. Guimarães C.R., Rai B.K., Munchhof M.J., Liu S., Wang J., Bhattacharya S.K., et al. Understanding the impact of the P-loop conformation on kinase selectivity. J. Chem. Inf. Model. 2011, 51:1199-1204.
19. Hari S.B., Perera B.G., Ranjitkar P., Seeliger M.A., Maly D.J. Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src. ACS Chem. Biol. 2013, 8:2734-2743.
20. Huang S.F., Liu H.P., Li L.H., Ku Y.C., Fu Y.N., Tsai H.Y., et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin. Cancer Res. 2004, 10:8195-8203.
21. Jänne P.A., Gray N., Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat. Rev. Drug Discovery 2009, 8:709-723.
22. Janne P.A., Ramalingam S.S., Yang J.C.-H., Ahn M.J., Kim D.-W., Kim S.-W., et al. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC). Clin. Oncol. 2014, 32:5s.
23. Kabsch W. XDS. Acta Crystallogr. Sect. D. 2010, 2010(D66):125-132.
24. Kim Y., Ko J., Cui Z.-Y., Abolhoda A., Ahn J.S., Ou S.-H., Ahn M.-Y., Park K. The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol. Cancer Ther. 2012, 11:784-791.
25. Kosaka T., Yatabe Y., Endoh H., Kuwano H., Takahashi T., Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004, 64:8919-8923.
26. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350:2129-2139.
27. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 2010, 362:2380-2388.
28. McPhillips T.M., McPhillips S.E., Chiu H.J., Cohen A.E., Deacon A.M., Ellis P.J., Garman E., Gonzalez A., Sauter N.K., Phizackerley R.P., Soltis S.M., Kuhn P. Blu-Ice and the distributed control system: software for data acquisition and instrument control at macromolecular crystallography beamlines. J. Synchrotron Radiat. 2002, 9:401-406.
29. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010, 11:121-128.
30. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009, 361:947-957.
31. Murshudov G.N., Skubák P., Lebedev A.A., Pannu N.S., Steiner R.A., Nicholls R.A., Winn M.D., Long F., Vagin A.A. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. 2011, D67:355-367.
32. Nunes M., Shi C., Grenberger L.M. Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal human keratinocytes. Mol. Cancer Ther. 2004, 3:21-27.
33. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
34. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:13306-13311.
35. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005, 2:e73.
36. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012, 13:239-246.
37. Sanderson K. Irreversible kinase inhibitors gain traction. Nat. Rev. Drug Discovery 2013, 12:649-651.
38. Seeliger M.A., Ranjitkar P., Kasap C., Shan Y., Shaw D.E., Shah N.P., Kuriyan J., Maly D.J. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. Cancer Res. 2009, 69:2384-2392.
39. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 2007, 7:169-181.
40. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I.I., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst. 2005, 97:339-346.
41. Smaill J.B., Rewcastle G.W., Bridges A.J., Zhou H., Showalter H.D.H., Fry D.W., Nelson J.M., Sherwood V., Elliott W.L., Vincent P.W., DeJohn D., Loo J.A., Gries K.D., Chan O.H., Reyner E.L., Lipka E., Denny W.A. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J. Med. Chem. 2000, 43:1380-1397.
42. Solca F., Dahl G., Zoephel A., Bader G., Sanderson M., Klein C., Kraemer O., Himmelsbach F., Haaksma E., Adolf G.R. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J. Pharm. Exp. Ther. 2012, 343:342-350.
43. Sos M.L., Rode H.B., Heynck S., Peifer M., Fischer F., Klüter S., Pawar V.G., Reuter C., Heuckmann J.M., Weiss J., Ruddigkeit L., Rabiller M., Koker M., Simard J.R., Getlik M., Yuza Y., Chen T.-H., Greulich H., Thomas R.K., Rauh D. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res. 2010, 70:868-874.
44. Tsou H.-R., Overbeek-Klumpers E.G., Hallett W.A., Reich M.F., Floyd M.B., Johnson B.D., Michalak R.S., Nilakantan R., Discafani C., Golas J., Rabindran S.K., Shen R., Shi X., Wang Y.-F., Upeslacis J., Wissner A. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J. Med. Chem. 2005, 48:1107-1131.
45. Wissner A., Overbeek E., Reich M.F., Floyd M.B., Johnson B.D., Mamuya N., Rosfjord E.C., Discafani C., Davis R., Shi X., Rabindran S.K., Gruber B.C., Ye F., Hallet W.A., Nilakantan R., Shen R., Wang Y.-F., Greenberger L.M., Tsou H.-R. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J. Med. Chem. 2003, 46:49-63.
46. Yosaatmadja Y., Patterson A.V., Smaill J.B., Squire C.J. The 1.65Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognition. Acta Crystallogr. Sect. D: Biol. Crystallogr. 2015, 71:525-533.
47. Yun C.H., Boggon T.J., Li Y., Woo M.S., Greulich H., Meyerson M., et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007, 11:217-227.
48. Zhang X., Gureasko J., Shen K., Cole P.A., Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006, 125:1137-1149.
49. Zhou W., Ercan D., Chen L., Yun C.H., Li D., Capelletti M., Cortot A.B., Chirieac L., Iacob R.E., Padera R., Engen J.R., Wong K.K., Eck M.J., Gray N.S., Jänne P.A. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009, 462:1070-1074.
50. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011, 12:735-742.